| abstract |
The present invention provides that an antibody that binds to the immunoglobulin-like (Ig) domain of the extracellular domain (ECD) of IGSF11 (VSIG3) can also inhibit the interaction between IGSF11 and an IGSF11 receptor, e.g., VSIR (VISTA), It is based on the surprising finding that inhibition of this interaction can sensitize tumor cells to anti-tumor immune responses. In particular, the present invention provides products, compositions and methods of treatment of diseases using antigen binding proteins targeting the Ig domain of IGSF11-ECD, including those that are modulators of IGSF11, e.g., inhibitors of IGSF11-interaction with VSIR. to provide. In addition, a method of sensitizing and/or killing cells associated with a proliferative disorder to the cytotoxic effect of a cell-mediated immune response, and/or in the Ig domain of an IGSF11 inhibitor, e.g., IGSF11-ECD Several related aspects are provided, including methods of treating a proliferative disease, as well as methods of detection, diagnosis, and screening using the binding antibody. |